Children and adolescents with type 2 diabetes had an improvement in HbA1c at 26 weeks with a once-daily oral GLP-1, according ...

Obesity therapeutics now represent ~$98B and 4.6% share, climbing to the fourth-largest category, with ~190 pipeline assets ...

Experts say any short-term financial benefit will be outweighed by long-term health costs related to obesity ...

Lilly plans to file Foundayo with the FDA for type 2 diabetes by end of Q2 after the ACHIEVE-4 trial met its primary ...

The FDA recalled multiple cough drops in 2026 over quality concerns. Learn which products are affected, why they were ...

Some Texans on SNAP say the ban on using food stamps to buy sugary drinks and candy prevents quick fixes to low blood sugar ...

Whether you’re hauling groceries or swimming faster laps, the amount of vigorous exercise you get matters and can slash your ...

For Dr. Joseph Cacchione, the math on GLP-1 drugs stopped making sense.

In an exclusive interview to Times Now Digital, Surbhi Chawla opened up about her experience with Mounjaro, a weight loss ...

Last patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with topline results expected in June 2026A non-invasive topical treatment for diabetic macular edema ...

Buy the dip on Abbott (ABT): diversified healthcare growth, Exact Sciences boost, strong dividend, and discounted ...